Скачать с ютуб The Effect of Nintedanib in IPF Subgroups в хорошем качестве

The Effect of Nintedanib in IPF Subgroups

This video is available for 0.25 AMA PRA Category 1 Credit(s)™ Click here to view CME and claim credit: https://bit.ly/3dYIkCc Listen to Lisa Lancaster, MD and Luca Richeldi, MD, PhD, report on current publications, posters, and sessions from a recent pulmonary conference. For more education from this series click here: https://bit.ly/3pE4ixE Lisa Lancaster, MD, has served on advisory boards for Bellerophon, Boehringer Ingelheim Pharmaceuticals, Inc, Genentech, Magnolia Therapeutics, Galapagos, Global Blood Therapeutics, and Theravance. She has also participated in contract research for Biogen, Boehringer Ingelheim Pharmaceuticals, Inc, Bellerophon, Celgene, Galacto, Galapagos, and Novartis. Luca Richeldi, MD, PhD, has participated in contract research for Boehringer Ingelheim Pharmaceuticals, Inc and Roche. He has also served as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc, Fibrogen, Nitto, and Roche. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. This information is intended for health care providers. This activity is supported by an educational grant from Genentech.